Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, has received funding from Biomedical Advanced Research and Development Authority (BARDA) to support the onshoring of Paratek manufacturing activities for NUZYRA. The reimbursement cost for the onshoring and security requirement activities is projected to total approximately $20 million. In December 2019, BARDA, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of H...